Answers are grounded in this paper and cite their sources.
Observational study shows baricitinib improves pain and health-related quality of life in rheumatoid arthritis, indicating better disease remission.
Objectives This real-world study evaluated the effectiveness of baricitinib on activities of daily living (ADL) and health-related quality of life (HRQoL) in patients with rheumatoid arthritis (RA) in Japan and explored the association between early pain and fatigue improvements and 12-month remission. Methods The study involved patients with RA aged ≥20 who initiated baricitinib and were followed for 12 months. Patient-reported outcomes (PROs) were assessed using visual analogue scale, Locomo 5, EQ-5D-5L, and SF-36 subscales. Results The study included 353 patients (mean age 63.4 years). Baricitinib substantially reduced pain levels from a mean (SD) of 48.4 (26.5) mm, fatigue levels from 42.3 (28.3) mm, and morning stiffness from 51.8 (126.9) min at baseline, to 25.2 (21.4) mm, 24.3 (22.7) mm, and 15.8 (38.7) min, respectively, at 12 months. Clinically meaningful improvements were observed in ADL (Locomo 5 scores: 6.9 [5.7] to 4.7 [5.3]) and HRQoL (EQ-5D-5L index scores: 0.700 [0.217] to 0.829 [0.166]) over 12 months. Logistic regression analysis revealed that early improvements in pain and fatigue were predictive of disease remission at 12 months. Conclusion Baricitinib improved PROs in patients with RA in Japan, with early symptom relief predicting mid-term disease remission.
No takes yet. Share an insight, caveat, or question.
Kaneko et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: